Outset Medical, Inc. (OM)
NASDAQ: OM · Real-Time Price · USD
18.45
+0.84 (4.77%)
At close: Jul 25, 2025, 4:00 PM
18.53
+0.08 (0.43%)
After-hours: Jul 25, 2025, 4:20 PM EDT
Outset Medical Stock Forecast
Stock Price Forecast
The 2 analysts that cover Outset Medical stock have a consensus rating of "Buy" and an average price target of $33, which forecasts a 78.86% increase in the stock price over the next year. The lowest target is $21 and the highest is $45.
Price Target: $33 (+78.86%)
Analyst Consensus: Buy
* Price targets were last updated on May 21, 2025.
Analyst Ratings
The average analyst rating for Outset Medical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $14 → $21 | Hold | Maintains | $14 → $21 | +13.82% | May 21, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $12 → $14 | Hold | Maintains | $12 → $14 | -24.12% | May 8, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $45 | Hold | Reiterates | $45 | +143.90% | Jan 7, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $90 → $45 | Buy → Hold | Downgrades | $90 → $45 | +143.90% | Aug 8, 2024 |
| TD Cowen | TD Cowen | Strong Buy Maintains $135 → $45 | Strong Buy | Maintains | $135 → $45 | +143.90% | Aug 8, 2024 |
Financial Forecast
Revenue This Year
125.97M
from 113.69M
Increased by 10.80%
Revenue Next Year
141.08M
from 125.97M
Increased by 11.99%
EPS This Year
-5.33
from -36.95
EPS Next Year
-3.95
from -5.33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 128.7M | 147.0M | 169.9M | ||
| Avg | 126.0M | 141.1M | 156.9M | ||
| Low | 119.6M | 131.7M | 144.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 13.2% | 16.7% | 20.4% | ||
| Avg | 10.8% | 12.0% | 11.2% | ||
| Low | 5.2% | 4.6% | 2.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.85 | -2.36 | -1.51 | ||
| Avg | -5.33 | -3.95 | -3.79 | ||
| Low | -7.82 | -8.33 | -7.36 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.